- Home
- ACIU
ACIU
AC Immune SA
as 07-26-2024 4:00pm EST
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Upcoming Earnings Alert:
Get ready for potential market movements as AC Immune SA ACIU prepares to release earnings report on 02 Aug 2024.
| Founded: | 2003 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 344.2M | IPO Year: | 2016 |
| Target Price: | $12.00 | AVG Volume (30 days): | 236.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.20 - $5.14 | Next Earning Date: | 08-02-2024 |
| Revenue: | $16,819,318 | Revenue Growth: | 276.14% |
| Revenue Growth (this year): | 315.09% | Revenue Growth (next year): | 96.23% |
Latest AC Immune SA News
ACIU Breaking Stock News: Dive into ACIU Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Sector Update: Health Care Stocks Decline Late Afternoon
MT Newswires
a day ago
Sector Update: Health Care
MT Newswires
a day ago
AC Immune Shares Surge After Active-Immunotherapy Candidate Gets FDA Fast Track Designation for Alzheimer's Disease
Pharmaceutical Technology
a day ago
AC Immune wins FDA fast track for Alzheimer’s vaccine
GlobeNewswire
2 days ago
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
GlobeNewswire
11 days ago
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
Simply Wall St.
a month ago
Here's Why Shareholders May Want To Be Cautious With Increasing AC Immune SA's (NASDAQ:ACIU) CEO Pay Packet
Zacks
a month ago
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
Compare ACIU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACIU AC Immune SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.